Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.66 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.62 |
| ▸ | JAK3 | P52333 | 4/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.59 |
| ▸ | INSR | P06213 | 5/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518595 | 0.90 | JAK2 (0.60) | JAK2PTK2JAK3ALKINSR | |
| SCHEMBL519908 | 0.90 | JAK2 (0.80) | JAK2PTK2JAK3ALKINSR | |
| SCHEMBL521373 | 0.90 | JAK2 (0.62) | JAK2PTK2JAK3ALKINSR | |
| SCHEMBL519828 | 0.87 | JAK2 (0.64) | JAK2PTK2JAK3ALKINSR | |
| SCHEMBL519183 | 0.87 | JAK2 (0.72) | JAK2PTK2JAK3ALKINSR | |
| SCHEMBL13465628 | 0.86 | JAK2 (0.82) | JAK2PTK2JAK3 | |
| SCHEMBL522206 | 0.86 | ALK (0.61) | JAK2PTK2ALKINSRCYP3A4 | |
| SCHEMBL519863 | 0.85 | JAK2 (0.62) | JAK2PTK2JAK3ALKINSR | |
| SCHEMBL519816 | 0.84 | JAK2 (0.76) | JAK2PTK2JAK3ALKINSR | |
| SCHEMBL519146 | 0.83 | ALK (0.64) | JAK2PTK2ALKINSRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | claimed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | claimed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |